In Corporate News, Science News

The British Journal of Cancer Research has just released a new paper co-authored by Nascent Biotech founder Dr. Mark C. Glassy entitled, “Prionogenicity of vimentin surmised from the sequelog of anti-idiotypic antibodies toward the paratope of malignant associatedautologous anti-vimentin antibody, CLN-IgG (Pritumumab)”.

Click here to download the paper.

Click here to download the supplementary information.

Recent Posts
Nascent Biotech logoNascent Biotech logo